FORMULATION AND EVALUATION OF TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING ANTI-INFLAMMATORY AGENT

Aim of the present study was to develop site-specific drug delivery system of lornoxicam for the treatment of arthritis, pain etc., which has excellent activity on inhibition of Cyclooxygenase-1 and Cyclooxygenase-2 enzymes. The formulations were developed by utilizing variouspolymers such as hydroxy propyl methyl cellulose and Eudragit RL-100 by solvent casting technique by the use of plasticizer (PEG-400 & DBT). The calibration curve of lornoxicam was developed in methanol/water. Compatibility study was carried out by FT-IR and Differential scanning colorimetry. The formulations were evaluated for thickness, folding endurance, weight variation, drug content, percent moisture loss, tensile strength. In vitro drug release study was also carried out by using PBS pH 7.4 and the samples were analyzed UV-spectrophotometrically at 374 nm. FT-IR and DSC study revealed no interaction between drug and polymers. Formulations shown good uniformity of drug content, there was no any kind of effect on moisture loss test. Formulations showed thickness within the range of (0.072 to 0.119). Formulation F1, F2, F5 & F6 showed good tensile strength. By increasing the concentration of Eudragit RL-100 in the formulation tensile strength, and folding endurance increases. Formulation F6 shows the release of drug 96.74% at the end of 12 h and was considered as a best formulation. A short?term stability study of the optimized formulation (F6) was also carried out at 400C for three months. At periodic interval 0, 30, 60, and 90 days a known quantity of sample was withdrawn and then analyzed for drug content and in vitro drug release studies, results showed a good content of uniformity and 95.23% release was observed at the end of 90 days. After a short-term stability study, there was no or very little amount of degradation was observed.